Semaglutide Dosage Guide 2026: Trials vs Reported Use

Turn a milligram dose into a reading on the barrel

Four fields, then the reading: the milligrams in the vial, the milliliters of water that went in, the barrel scale, and the dose being converted. Out come the concentration, the volume, and the unit count.

This page, or the calculator page: this one is the compound reference, and it owns the semaglutide dosage question: what the trials assigned, what the labels specify, and how the reported schedules compare with both. For the tool on its own, the semaglutide dosage calculator runs the same conversion with the Ozempic and Wegovy label concentrations laid out beside it.

Does the trial dose match the internet dose?

Semaglutide is the one compound on this site where the comparison is genuinely close: the trial schedule and the label schedule are the same schedule, so the left-hand column below is unusually well populated. What the right-hand column does with it is still a separate question.

The label prints one ramp. The posts print a dozen, and the ramp itself was written for a pen rather than for a vial that arrives as powder.

What actually separates those two columns: one of them was measured in 1,961 people and then written onto a label. The other is what happens when that label meets a vial nobody approved. Which side anyone is on is a conversation for a doctor who knows their history. What this page holds is the trials, the label, and the arithmetic between them.

How does the units math work?

Done once, in general, with nobody's dose in it: the figures below belong to a vial and a volume of water.

A 5mg vial in 1mL: a 5mg vial reconstituted with 1mL of bacteriostatic water holds 5mg per mL, the same thing as 5,000mcg per mL.

On the barrel: one hundred units fill a milliliter on a U-100, which makes a single unit a hundredth of a milliliter, worth 50mcg, or 0.05mg in this vial. 0.25mg lands on 5 units, 1mg on 20, and 2.4mg on 48.

A 10mg vial in that same 1mL: the concentration doubles, to 10mg per mL.

So every mark doubles with it: a unit carries 0.1mg where it carried 0.05mg, which puts the same 2.4mg on 24 units, not 48, and 0.25mg on two and a half.

Which is what a posted "20 units" cannot carry: the vial size it was worked out on. Without that, the two rows above turn the same reading into 1mg and into 2mg with equal authority.

The pen exception, which is why this whole section is optional on the approved products: Ozempic and Wegovy pens arrive pre-filled at fixed doses, so nothing is reconstituted and no unit conversion happens at all. Everything above exists because a research vial arrives as powder and hands both decisions back to whoever mixes it.

And the second of those decisions is the barrel: the scale table sets a U-40 mark at 2.5 times the volume of a U-100 mark, so a count derived on one scale and read on the other misses by that factor while the barrel goes on printing the same "20 units". No pen has that failure mode; every vial does.

Does 2.4mg of semaglutide have one units number?

No, and the spread is a factor of two: at 5mg per mL, a 5mg vial plus 1mL of water, 2.4mg reads as 48 units on a U-100 syringe. At 10mg per mL, a 10mg vial plus 1mL, the same 2.4mg reads as 24 units.

What makes 2.4mg a special case anyway: it is the only figure on this page that came off an approved label, and the label attaches it to a pre-filled pen where no unit count is ever taken. The 48 and the 24 above exist only because the same milligram figure got carried onto a vial the label does not cover, and our dose math index is largely a record of what happens next.

What's not known yet?

What is approved, and under which application: semaglutide holds FDA approvals under brand names: Ozempic for type 2 diabetes under NDA 209637, Wegovy for weight management and cardiovascular risk reduction under NDA 215256, Rybelsus as oral tablets for type 2 diabetes under NDA 213051. Read off the current labels and the Drugs@FDA application records on 29 July 2026.

What moved recently: Wegovy tablets came through as a new dosage form under NDA 218316, first approved 22 December 2025, and the label's tablet strengths run to 25mg. The 7.2mg once-weekly injection sold as Wegovy HD arrived with supplement S-029 to NDA 215256, whose approval letter describes it as "the addition of a new Wegovy injection 7.2 mg subcutaneous weekly dose for weight reduction and maintenance long term", approved March 2026. The Wegovy label now also carries a MASH indication, and the Ozempic label carries reduction of the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death in type 2 diabetes with chronic kidney disease.

The key distinction: the approvals cover the brand pens, prefilled syringes, and tablets, fixed-dose products made by the manufacturer. Research-grade vials are not the approved product.

The regulatory line: FDA determined the semaglutide injection shortage resolved on 21 February 2025, and its compounder-policy page records the enforcement-discretion windows closing after that, so compounding of copycat versions now sits inside narrow conditions. The agency has also warned companies illegally selling unapproved semaglutide, tirzepatide or retatrutide "falsely labeled 'for research purposes' or 'not for human consumption'", sold direct to consumers with dosing instructions and of unknown quality.

Where the published record stops:

• The obesity trials we pulled top out at 104 weeks (STEP 5), and SELECT's mean follow-up was 39.8 months, as of our 20 July 2026 check.
• In the STEP 1 extension cohort, stopping meant regaining: two-thirds of the lost weight came back within a year. What years of on-again, off-again use do is not in the literature we pulled.
• No verified data on the community vial patterns that dominate online discussion, as of our 20 July 2026 check. None of those patterns has been studied in a controlled trial.

As of our 20 July 2026 check, nothing published closes any of those three.

And one that sits in front of all three: the number on an approved carton sits on an FDA-approved label, under one of the application numbers above. The number on a research vial sits on a label its seller printed.

Four things no approved review covers: identity, purity, sterility, and whether the concentration on the label is the concentration in the vial. FDA states that unapproved versions do not undergo its review for safety, effectiveness and quality before they are marketed.

And the fourth is the one the FDA error reports run through: the agency attributes hospitalizations to milligram-to-unit conversion errors, which are the failure mode of arithmetic that started from an assumed concentration rather than a verified one.

Which is a sourcing question before it is a dosing one: the strength on an approved pen was reviewed, and the strength on a research vial was typed, and that difference would worry us ahead of any milligram figure.

How this page is sourced

Abstracts and labels, read directly: every trial figure on this page came off the cited paper itself, and none of it came off a summary page.

The regulatory documents: the approval status, escalation schedule, adverse-event counts and FDA compounding position are each printed below as their own reference, not summarized from memory. They were pulled live on 29 July 2026.

Twelve sources, papers and regulator documents both: listed below, with their DOIs and PubMed IDs where they exist. Each is listed below with its identifier, and every figure on this page traces back to one of them.

The bar every number here has to clear: the site's sourcing and citation-verification standard lives on the methodology page. Any number here that ever gets corrected gets corrected there first.

Last reviewed: 19 July 2026.

1. 1

   Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183. PMID 33567185.

2. 2

   Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021;397(10278):971-984. doi:10.1016/S0140-6736(21)00213-0. PMID 33667417.

3. 3

   Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022;28(10):2083-2091. doi:10.1038/s41591-022-02026-4. PMID 36216945.

4. 4

   Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564. doi:10.1111/dom.14725. PMID 35441470.

5. 5

   Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375(19):1834-1844. doi:10.1056/NEJMoa1607141. PMID 27633186.

6. 6

   Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. doi:10.1056/NEJMoa2307563. PMID 37952131.

7. 7

   Novo Nordisk. Wegovy (semaglutide) injection, for subcutaneous use, and Wegovy (semaglutide) tablets, for oral use: prescribing information, indications and usage, dosage and administration, and dosage forms and strengths, including Table 1. Revised June 2026. Source of the escalation schedule, the maintenance dosages, the Wegovy HD strength, the tablet strengths and the MASH indication. DailyMed, U.S. National Library of Medicine. Retrieved 29 July 2026, HTTP 200. Current label.

8. 8

   Novo Nordisk. Ozempic (semaglutide) injection, prescribing information, indications and usage and dosage and administration. Source of the kidney-risk and cardiovascular indications quoted above. DailyMed, U.S. National Library of Medicine. Retrieved 29 July 2026, HTTP 200. Current label.

9. 9

   U.S. Food and Drug Administration, Drugs@FDA application records: NDA 209637 (Ozempic, first approval 5 December 2017), NDA 215256 (Wegovy, Wegovy HD and Wegovy FlexTouch, first approval 4 June 2021), NDA 218316 (Wegovy tablets, new dosage form, first approval 22 December 2025), NDA 213051 (Rybelsus, first approval 20 September 2019). Queried through the openFDA drugsfda endpoint 29 July 2026, HTTP 200. The single approval letter covering NDA 215256/S-029 and NDA 218316/S-005 does two different things, and only the first adds a dose: S-029 "provides for the addition of a new Wegovy injection 7.2 mg subcutaneous weekly dose for weight reduction and maintenance long term", while S-005 provides for alignment of the combined Wegovy injection and tablet prescribing information based on that addition. It is at accessdata.fda.gov (HTTP 200).

10. 10

    U.S. Food and Drug Administration. FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products. Human drug compounding; content current as of 26 July 2024. Source of the hospitalisation reports, the milligram-to-unit conversion errors, and the five-to-tenfold overdose examples. Retrieved 29 July 2026, HTTP 200. fda.gov, dosing-error alert.

11. 11

    U.S. Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. Drug alerts and statements, content current as of 1 April 2026, carrying the dated 21 February 2025 entry determining the semaglutide injection shortage resolved and the enforcement-discretion windows that followed. Retrieved 29 July 2026, HTTP 200. fda.gov, compounder policy update.

12. 12

    U.S. Food and Drug Administration. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. Drug alerts and statements, content current as of 15 June 2026. Source of the 990 adverse-event reports for compounded semaglutide as of 31 May 2026, and of the warnings to companies selling product falsely labeled for research purposes. Retrieved 29 July 2026, HTTP 200. fda.gov, unapproved GLP-1 concerns.